For 25 years, Iceland’s deCODE Genetics has been one of the most powerful and prolific producers and analyzers of human genomic sequence data. Founded by neurologist Kári Stefánsson, deCODE has ...
Ten years after acquiring deCODE Genetics, Amgen’s collaboration with the Icelandic genetic sleuths has only blossomed, expanding from drug discovery to clinical development. The partners celebrated ...
REYKJAVIK, Iceland, Jan. 29, 2024 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland, Denmark, and the USA published a study today in Nature ...
Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial ...
Scientists at deCODE genetics, a subsidiary of Amgen, have published a study in Nature Communications, comparing over 110 thousand patients with autoimmune thyroid disease (AITD) from Iceland, Finland ...
REYKJAVIK, Iceland, June 24, 2020 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from the Icelandic healthcare system, University of Iceland and the ...
The scientists at deCODE Genetics, a subsidiary of Amgen, sought to deepen the understanding of cis-acting influences of sequence variants on CpG methylation. In the study, the scientists were able to ...
Scientists at deCODE genetics/Amgen have constructed a complete map of how human DNA is mixed as it is passed down during reproduction. The map marks a major step in the understanding of genetic ...
Reykjavik, ICELAND, October 8, 2008 – deCODE genetics (Nasdaq:DCGN) today announced the launch of deCODE BreastCancer™, a new tool for assessing risk of the common forms of breast cancer. For the ...
What began as discussions around a scientific collaboration a few months ago blossomed into a full acquisition deal between Amgen Inc., of Thousand Oaks, Calif., and DeCode Genetics, of Reykjavik, ...
Amgen Inc. on Monday said that it has agreed to buy Decode Genetics, an Icelandic company that can help Amgen develop personalized drug therapies, for $415 million. The Reykjavik human genetics ...
Amgen Inc. agreed to acquire Iceland-based deCODE genetics Inc., which identifies genetic risk factors for dozens of diseases, for about $415 million. Amgen President and Chief Executive Robert A.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results